Last reviewed · How we verify
D-CIK
At a glance
| Generic name | D-CIK |
|---|---|
| Sponsor | Shenzhen Hornetcorn Bio-technology Company, LTD |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer (NA)
- Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (PHASE1, PHASE2)
- Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma (PHASE2, PHASE3)
- Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma (PHASE2)
- Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors (PHASE3)
- Safety and Efficacy of γδ T Cell Against Gastric Cancer (PHASE1, PHASE2)
- A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma (PHASE2)
- Evaluation of Cytokine-induced Killer (CIK) Cells as Therapy or Adjuvant Treatment for Advanced HCC (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- D-CIK CI brief — competitive landscape report
- D-CIK updates RSS · CI watch RSS
- Shenzhen Hornetcorn Bio-technology Company, LTD portfolio CI